Prostaglandin D2 mediates neuronal damage by amyloid-β or prions which activates microglial cells

被引:34
作者
Bate, C [1 ]
Kempster, S [1 ]
Williams, A [1 ]
机构
[1] Univ London Royal Vet Coll, Dept Pathol & Infect Dis, N Mymms AL9 7TA, Herts, England
关键词
amyloid-beta; prion; cyclo-oxygenase; prostaglandins; CD14; microglial cells;
D O I
10.1016/j.neuropharm.2005.09.008
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Microglial cells killed neurons damaged following incubation with sub-lethal concentrations of peptides derived from either the human prion protein (HuPrP82-146) or amyloid-beta(1-42) (a peptide found in Alzheimer's disease). HuPrP82-146 or amyloid-beta(1-42) induced phenotypic changes in neurons that caused them to bind a CD14-IgG chimera. In co-cultures microglial cells produced interleukin (IL)-6 in response to HuPrP82-146 or amyloid-beta(1-42) damaged neurons. The binding of the CD14-IgG chimera to HuPrP82-146 or amyloid-beta(1-42) damaged neurons was reduced by pre-treatment with cyclo-oxygenase (COX)-1 inhibitors and in co-cultures, COX-1 inhibitors significantly increased neuronal survival. Studies with individual prostaglandins demonstrated that the addition of prostaglandin D-2, or prostaglandin E-2, but not other prostaglandins (F-2 alpha, H-2, 12 or 15-dJ(2)), mimicked the effects of amyloid-beta(1-42) on neurons. Thus, prostaglandin D-2 or E-2 damaged neurons bound the CD14-IgG chimera, and in co-cultures prostaglandin D-2 damaged neurons activated microglial cells. These effects were mediated via the DP prostanoid receptor; DP receptor agonists BW245C or SQ27986 induced neuronal damage, while the DP receptor antagonist BWA868C was neuroprotective in cocultures. These results indicate that prostaglandin D2, produced following activation of COX-1 by sub-lethal concentrations of HuPrP82-146 or amyloid-beta(1-42), causes phenotypic changes in neurons that activates microglial cells and leads to neuronal loss. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:229 / 237
页数:9
相关论文
共 37 条
[1]   Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].
Aisen, PS ;
Schafer, KA ;
Grundman, M ;
Pfeiffer, E ;
Sano, M ;
Davis, KL ;
Farlow, MR ;
Jin, S ;
Thomas, RG ;
Thal, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826
[2]   Killing of prion-damaged neurones by microglia [J].
Bate, C ;
Reid, S ;
Williams, A .
NEUROREPORT, 2001, 12 (11) :2589-2594
[3]   Microglia kill amyloid-β1-42 damaged neurons by a CD14-dependent process [J].
Bate, C ;
Veerhuis, R ;
Eikelenboom, P ;
Williarns, A .
NEUROREPORT, 2004, 15 (09) :1427-1430
[4]   Frequency of stages of Alzheimer-related lesions in different age categories [J].
Braak, H ;
Braak, E .
NEUROBIOLOGY OF AGING, 1997, 18 (04) :351-357
[5]   Role of microglia and host prion protein in neurotoxicity of a prion protein fragment [J].
Brown, DR ;
Schmidt, B ;
Kretzschmar, HA .
NATURE, 1996, 380 (6572) :345-347
[6]  
DEL BR, 1995, NEUROSCI LETT, V188, P70
[7]   The LPS receptor (CD14) links innate immunity with Alzheimer's disease [J].
Fassbender, K ;
Walter, S ;
Kuhl, S ;
Landmann, R ;
Ishii, K ;
Bertsch, T ;
Stalder, AK ;
Muehlhauser, F ;
Liu, Y ;
Ulmer, AJ ;
Rivest, S ;
Lentschat, A ;
Gulbins, E ;
Jucker, M ;
Staufenbiel, M ;
Brechtel, K ;
Walter, J ;
Multhaup, G ;
Penke, B ;
Adachi, Y ;
Hartmann, T ;
Beyreuther, K .
FASEB JOURNAL, 2004, 18 (01) :203-205
[8]   NEUROTOXICITY OF A PRION PROTEIN-FRAGMENT [J].
FORLONI, G ;
ANGERETTI, N ;
CHIESA, R ;
MONZANI, E ;
SALMONA, M ;
BUGIANI, O ;
TAGLIAVINI, F .
NATURE, 1993, 362 (6420) :543-546
[9]   Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease [J].
Ho, L ;
Purohit, D ;
Haroutunian, V ;
Luterman, JD ;
Willis, F ;
Naslund, J ;
Buxbaum, JD ;
Mohs, RC ;
Aisen, PS ;
Pasinetti, GM .
ARCHIVES OF NEUROLOGY, 2001, 58 (03) :487-492
[10]   RELATIONSHIP OF MICROGLIA AND ASTROCYTES TO AMYLOID DEPOSITS OF ALZHEIMER-DISEASE [J].
ITAGAKI, S ;
MCGEER, PL ;
AKIYAMA, H ;
ZHU, S ;
SELKOE, D .
JOURNAL OF NEUROIMMUNOLOGY, 1989, 24 (03) :173-182